Common use of About Celgene Clause in Contracts

About Celgene. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company’s web site at xxx.xxxxxxx.xxx. This release contains forward-looking statements which are subject to known and unknown risks, delays, uncertainties and other factors not under either company’s control, which may cause actual results, performance or achievements of either company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements. These factors include results of current or pending research and development activities, actions by the FDA and other regulatory authorities, need for additional capital and other factors, which with respect to Celgene are further described in Celgene’s filings with the Securities and Exchange Commission such as Celgene’s 10K, 10Q and 8K reports. GLOBEIMMUNE CONTACT: Xxxxxxx Xxxx Chief Business Officer GlobeImmune, Inc. T: 000-000-0000 xxxxxxxxxxx@xxxxxxxxxxx.xxx [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. MEDIA CONTACT: Xxxxx Xxxxxxx, Ph.X. Xxxxx Partners T: 619-528-2217 M: 000-000-0000 xxxxx.xxxxxxx@xxxxxxxxxxxxxxxx.xxx CELGENE CONTACT: Xxxx Xxxxxxxx Associate Director, Public Relations Celgene Corporation T: 000-000-0000 xxxxxxxxx@xxxxxxx.xxx [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Schedule A Third Party Agreement(s) “Cooperative Research and Development Agreement (CRADA) for Intramural-PHS Clinical Research” between GlobeImmune, Inc. and The U.S. Department of Health and Human Services, as represented by National Cancer Institute, an Institute, Center, or Division of the NIH, effective May 8, 2008. “Materials Transfer Agreement” between GlobeImmune, Inc. and The Regents of the University of Colorado (Xxxxx XxXxxxxxx, Ph.D., principal investigator), effective February 18, 2009. “Materials Transfer Agreement” between GlobeImmune, Inc. and The Regents of the University of Colorado (Xxxxx XxXxxxxxx, Ph.D., principal investigator), effective March 5, 2009. [*] [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Schedule B Third Party License Agreement(s) Agreement, effective as of May 30, 2006, between The Regents of The University of Colorado and GlobeImmune (as successor-in-interest to Ceres Pharmaceuticals, Ltd.), and the Restated Intellectual Property License Agreement, dated September 18, 1997 (restating the Intellectual Property License Agreement, dated September 18, 1997, as amended March 18, 1998, June 1, 2001, and October 16, 2003), among the Regents of the University of Colorado, The University License Equity Holdings, Inc. (as successor to University Technology Corporation), and GlobeImmune, each as amended May 5, 2009 (collectively, the “CU Agreement”). Patent License Agreement between GlobeImmune and the National Institutes of Health or the Food and Drug Administration (referred to as PHS), agencies of the United States Public Health Service within the Department of Health and Human Services, dated June 12, 2007 (the “NIH License Agreement”).

About Celgene. Celgene Corporation, headquartered in Summit, New Jersey, Jersey is an integrated global biopharmaceutical pharmaceutical company engaged primarily in the discovery, development and commercialization of novel innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company’s web site website at xxx.xxxxxxx.xxx. This release contains forward-looking statements which are subject to known and unknown risks, delays, uncertainties and other factors not under either companyCelgene’s control, which may cause actual results, performance or achievements of either company Celgene to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements. These factors include results of current or pending research and development activities, actions by the FDA and other regulatory authorities, need for additional capital and other factors, which with respect to Celgene are further factors described in Celgene’s filings with the Securities and Exchange Commission such as Celgene’s its 10K, 10Q and 8K reports. GLOBEIMMUNE CONTACT: Celgene Corporation: Acceleron Pharma: Xxxxx Xxxxxx, 908-673-9059 Xxxxxx Xxxxx, 000-000-0000 Senior Vice President and Chief Financial Officer Vice President, Corporate Development or or Xxxxx X. Xxxx, 000-000-0000 Xxxx Xxxxxxx Xxxx Chief Business Officer GlobeImmune(Media) Vice President, Inc. TGlobal Corporate Communications Suda Communications LLC, tel: 000-000-0000 xxxxxxxxxxx@xxxxxxxxxxx.xxx THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amendedAND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. MEDIA CONTACT: Xxxxx Xxxxxxx, Ph.X. Xxxxx Partners T: 619-528-2217 M: 000-000-0000 xxxxx.xxxxxxx@xxxxxxxxxxxxxxxx.xxx CELGENE CONTACT: Xxxx Xxxxxxxx Associate Director, Public Relations Celgene Corporation T: 000-000-0000 xxxxxxxxx@xxxxxxx.xxx [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Schedule A Third Party Agreement(s) “Cooperative Research and Development Agreement (CRADA) for Intramural-PHS Clinical Research” between GlobeImmune, Inc. and The U.S. Department of Health and Human Services, as represented by National Cancer Institute, an Institute, Center, or Division of the NIH, effective May 8, 2008. “Materials Transfer Agreement” between GlobeImmune, Inc. and The Regents of the University of Colorado (Xxxxx XxXxxxxxx, Ph.D., principal investigator), effective February 18, 2009. “Materials Transfer Agreement” between GlobeImmune, Inc. and The Regents of the University of Colorado (Xxxxx XxXxxxxxx, Ph.D., principal investigator), effective March 5, 2009. [*] [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Schedule B Third Party License Agreement(s) Agreement, effective as of May 30, 2006, between The Regents of The University of Colorado and GlobeImmune (as successor-in-interest to Ceres Pharmaceuticals, Ltd.), and the Restated Intellectual Property License Agreement, dated September 18, 1997 (restating the Intellectual Property License Agreement, dated September 18, 1997, as amended March 18, 1998, June 1, 2001, and October 16, 2003), among the Regents of the University of Colorado, The University License Equity Holdings, Inc. (as successor to University Technology Corporation), and GlobeImmune, each as amended May 5, 2009 (collectively, the “CU Agreement”). Patent License Agreement between GlobeImmune and the National Institutes of Health or the Food and Drug Administration (referred to as PHS), agencies of the United States Public Health Service within the Department of Health and Human Services, dated June 12, 2007 (the “NIH License Agreement”).# # #

About Celgene. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company’s web site at xxx.xxxxxxx.xxx. This release contains forward-looking statements which are subject to known and unknown risks, delays, uncertainties and other factors not under either company’s control, which may cause actual results, performance or achievements of either company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements. These factors include results of current or pending research and development activities, actions by the FDA and other regulatory authorities, need for additional capital and other factors, which with respect to Celgene are further described in Celgene’s filings with the Securities and Exchange Commission such as Celgene’s 10K, 10Q and 8K reports. GLOBEIMMUNE CONTACT: Xxxxxxx Xxxx Chief Business Officer GlobeImmune, Inc. T: 000-000-0000 xxxxxxxxxxx@xxxxxxxxxxx.xxx [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 24b-2 of the Securities Exchange Act of 19331934, as amended. MEDIA CONTACT: Xxxxx Xxxxxxx, Ph.X. Xxxxx Partners T: 619-528-2217 M: 000-000-0000 xxxxx.xxxxxxx@xxxxxxxxxxxxxxxx.xxx CELGENE CONTACT: Xxxx Xxxxxxxx Associate Director, Public Relations Celgene Corporation T: 000-000-0000 xxxxxxxxx@xxxxxxx.xxx [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 24b-2 of the Securities Exchange Act of 19331934, as amended. Schedule A Third Party Agreement(s) “Cooperative Research and Development Agreement (CRADA) for Intramural-PHS Clinical Research” between GlobeImmune, Inc. and The U.S. Department of Health and Human Services, as represented by National Cancer Institute, an Institute, Center, or Division of the NIH, effective May 8, 2008. “Materials Transfer Agreement” between GlobeImmune, Inc. and The Regents of the University of Colorado (Xxxxx XxXxxxxxx, Ph.D., principal investigator), effective February 18, 2009. “Materials Transfer Agreement” between GlobeImmune, Inc. and The Regents of the University of Colorado (Xxxxx XxXxxxxxx, Ph.D., principal investigator), effective March 5, 2009. [*] [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 24b-2 of the Securities Exchange Act of 19331934, as amended. Schedule B Third Party License Agreement(s) Agreement, effective as of May 30, 2006, between The Regents of The University of Colorado and GlobeImmune (as successor-in-interest to Ceres Pharmaceuticals, Ltd.), and the Restated Intellectual Property License Agreement, dated September 18, 1997 (restating the Intellectual Property License Agreement, dated September 18, 1997, as amended March 18, 1998, June 1, 2001, and October 16, 2003), among the Regents of the University of Colorado, The University License Equity Holdings, Inc. (as successor to University Technology Corporation), and GlobeImmune, each as amended May 5, 2009 (collectively, the “CU Agreement”). Patent License Agreement between GlobeImmune and the National Institutes of Health or the Food and Drug Administration (referred to as PHS), agencies of the United States Public Health Service within the Department of Health and Human Services, dated June 12, 2007 (the “NIH License Agreement”).

About Celgene. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company’s web site at xxx.xxxxxxx.xxx. This release contains forward-looking statements which are subject to known and unknown risks, delays, uncertainties and other factors not under either company’s control, which may cause actual results, performance or achievements of either company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements. These factors include results of current or pending research and development activities, actions by the FDA and other regulatory authorities, need for additional capital and other factors, which with respect to Celgene are further described in Celgene’s filings with the Securities and Exchange Commission such as Celgene’s 10K, 10Q and 8K reports. GLOBEIMMUNE CONTACT: Xxxxxxx Xxxx Chief Business Officer GlobeImmune, Inc. T: 000-000-0000 xxxxxxxxxxx@xxxxxxxxxxx.xxx [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. MEDIA CONTACT: Xxxxx Xxxxxxx, Ph.X. Xxxxx Partners T: 619-528-2217 M: 000-000-0000 xxxxx.xxxxxxx@xxxxxxxxxxxxxxxx.xxx CELGENE CONTACT: Xxxx Xxxxxxxx Associate Director, Public Relations Celgene Corporation T: 000-000-0000 xxxxxxxxx@xxxxxxx.xxx [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Schedule A Third Party Agreement(s) “Cooperative Research and Development Agreement (CRADA) for Intramural-PHS Clinical Research” between GlobeImmune, Inc. and The U.S. Department of Health and Human Services, as represented by National Cancer Institute, an Institute, Center, or Division of the NIH, effective May 8, 2008. “Materials Transfer Agreement” between GlobeImmune, Inc. and The Regents of the University of Colorado (Xxxxx XxXxxxxxx, Ph.D., principal investigator), effective February 18, 2009. “Materials Transfer Agreement” between GlobeImmune, Inc. and The Regents of the University of Colorado (Xxxxx XxXxxxxxx, Ph.D., principal investigator), effective March 5, 2009. [*] [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Schedule B Third Party License Agreement(s) Agreement, effective as of May 30, 2006, between The Regents of The University of Colorado and GlobeImmune (as successor-in-interest to Ceres Pharmaceuticals, Ltd.), and the Restated Intellectual Property License Agreement, dated September 18, 1997 (restating the Intellectual Property License Agreement, dated September 18, 1997, as amended March 18, 1998, June 1, 2001, and October 16, 2003), among the Regents of the University of Colorado, The University License Equity Holdings, Inc. (as successor to University Technology Corporation), and GlobeImmune, each as amended May 5, 2009 (collectively, the “CU Agreement”). Patent License Agreement between GlobeImmune and the National Institutes of Health or the Food and Drug Administration (referred to as PHS), agencies of the United States Public Health Service within the Department of Health and Human Services, dated June 12, 2007 (the “NIH License Agreement”).